Obesity leads to asthma via various mechanisms including inflammatory signalling and fibrotic changes; therefore, recent studies have revealed that anti-inflammatory or anti-fibrotic drugs including roflumilast, anti-IL-17 and anti-IL-1β antibodies could have significant effects on obesity-induced asthma without significant weight loss10,23,24. The gene discussed is IL17A; the disease is obesity due to melanocortin 4 receptor deficiency.